Increased EBNA1-specific antibody response in primary-progressive multiple sclerosis
Epstein–Barr virus; Human cytomegalovirus; Multiple sclerosis
| Autores: | , , , , , , , , , , , , |
|---|---|
| Tipo de documento: | artigo |
| Estado: | Versão publicada |
| Data de publicação: | 2025 |
| País: | España |
| Recursos: | Departament de Salut de la Generalitat de Catalunya (DS) |
| Repositório: | Scientia. Dipòsit d'Informació Digital del Departament de Salut |
| OAI Identifier: | oai:scientiasalut.gencat.cat:11351/12789 |
| Acesso em linha: | http://hdl.handle.net/11351/12789 |
| Access Level: | Acceso aberto |
| Palavra-chave: | Immunoglobulines Esclerosi múltiple Infeccions per virus d'Epstein-Barr Antígens DISEASES::Virus Diseases::DNA Virus Infections::Herpesviridae Infections::Epstein-Barr Virus Infections DISEASES::Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases, CNS::Multiple Sclerosis::Multiple Sclerosis, Chronic Progressive CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Viral CHEMICALS AND DRUGS::Biological Factors::Antigens::Antigens, Nuclear::Epstein-Barr Virus Nuclear Antigens ENFERMEDADES::virosis::infecciones por virus ADN::infecciones por Herpesviridae::infecciones por virus de Epstein-Barr ENFERMEDADES::enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple::esclerosis múltiple crónica progresiva COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos víricos COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::antígenos::antígenos nucleares::antígenos nucleares del virus de Epstein-Barr |
| id |
ES_613f0deda3c319e1ee4fdae9a5fa5220 |
|---|---|
| oai_identifier_str |
oai:scientiasalut.gencat.cat:11351/12789 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| dc.title.none.fl_str_mv |
Increased EBNA1-specific antibody response in primary-progressive multiple sclerosis |
| title |
Increased EBNA1-specific antibody response in primary-progressive multiple sclerosis |
| spellingShingle |
Increased EBNA1-specific antibody response in primary-progressive multiple sclerosis Carbonell Mirabent, Pere Immunoglobulines Esclerosi múltiple Infeccions per virus d'Epstein-Barr Antígens DISEASES::Virus Diseases::DNA Virus Infections::Herpesviridae Infections::Epstein-Barr Virus Infections DISEASES::Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases, CNS::Multiple Sclerosis::Multiple Sclerosis, Chronic Progressive CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Viral CHEMICALS AND DRUGS::Biological Factors::Antigens::Antigens, Nuclear::Epstein-Barr Virus Nuclear Antigens ENFERMEDADES::virosis::infecciones por virus ADN::infecciones por Herpesviridae::infecciones por virus de Epstein-Barr ENFERMEDADES::enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple::esclerosis múltiple crónica progresiva COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos víricos COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::antígenos::antígenos nucleares::antígenos nucleares del virus de Epstein-Barr |
| title_short |
Increased EBNA1-specific antibody response in primary-progressive multiple sclerosis |
| title_full |
Increased EBNA1-specific antibody response in primary-progressive multiple sclerosis |
| title_fullStr |
Increased EBNA1-specific antibody response in primary-progressive multiple sclerosis |
| title_full_unstemmed |
Increased EBNA1-specific antibody response in primary-progressive multiple sclerosis |
| title_sort |
Increased EBNA1-specific antibody response in primary-progressive multiple sclerosis |
| dc.creator.none.fl_str_mv |
Carbonell Mirabent, Pere Comabella Lopez, Manuel Hegen, Harald Villar, Luisa M Rejdak, Konrad Sao Aviles, Augusto Behrens, Malina Sastre Garriga, Jaume Mongay-Ochoa, Neus Fissolo, Nicolás Miguel Gutiérrez Ruiz, Lucía Villacieros-Álvarez, Javier Montalban, Xavier |
| author |
Carbonell Mirabent, Pere |
| author_facet |
Carbonell Mirabent, Pere Comabella Lopez, Manuel Hegen, Harald Villar, Luisa M Rejdak, Konrad Sao Aviles, Augusto Behrens, Malina Sastre Garriga, Jaume Mongay-Ochoa, Neus Fissolo, Nicolás Miguel Gutiérrez Ruiz, Lucía Villacieros-Álvarez, Javier Montalban, Xavier |
| author_role |
author |
| author2 |
Comabella Lopez, Manuel Hegen, Harald Villar, Luisa M Rejdak, Konrad Sao Aviles, Augusto Behrens, Malina Sastre Garriga, Jaume Mongay-Ochoa, Neus Fissolo, Nicolás Miguel Gutiérrez Ruiz, Lucía Villacieros-Álvarez, Javier Montalban, Xavier |
| author2_role |
author author author author author author author author author author author author |
| dc.contributor.none.fl_str_mv |
Institut Català de la Salut [Comabella M, Fissolo N] Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Vall d’Hebron Hospital Universitari, Barcelona, Spain., Barcelona, Spain. Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED)-ISCIII, Madrid, Spain. [Hegen H] Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria. [Villar LM] Departments of Neurology and Immunology, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigacion Sanitaria, Madrid, Spain. [Rejdak K] Department of Neurology, Medical University of Lublin, Lublin, Poland. [Sao Avilés A, Sastre Garriga J, Mongay N, Carbonell Mirabent P, Gutiérrez L, Villacieros Álvarez J, Montalban X] Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Vall d’Hebron Hospital Universitari, Barcelona, Spain., Barcelona, Spain. Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED)-ISCIII, Madrid, Spain. [Behrens M] Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany Vall d'Hebron Barcelona Hospital Campus |
| dc.subject.none.fl_str_mv |
Immunoglobulines Esclerosi múltiple Infeccions per virus d'Epstein-Barr Antígens DISEASES::Virus Diseases::DNA Virus Infections::Herpesviridae Infections::Epstein-Barr Virus Infections DISEASES::Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases, CNS::Multiple Sclerosis::Multiple Sclerosis, Chronic Progressive CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Viral CHEMICALS AND DRUGS::Biological Factors::Antigens::Antigens, Nuclear::Epstein-Barr Virus Nuclear Antigens ENFERMEDADES::virosis::infecciones por virus ADN::infecciones por Herpesviridae::infecciones por virus de Epstein-Barr ENFERMEDADES::enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple::esclerosis múltiple crónica progresiva COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos víricos COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::antígenos::antígenos nucleares::antígenos nucleares del virus de Epstein-Barr |
| topic |
Immunoglobulines Esclerosi múltiple Infeccions per virus d'Epstein-Barr Antígens DISEASES::Virus Diseases::DNA Virus Infections::Herpesviridae Infections::Epstein-Barr Virus Infections DISEASES::Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases, CNS::Multiple Sclerosis::Multiple Sclerosis, Chronic Progressive CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Viral CHEMICALS AND DRUGS::Biological Factors::Antigens::Antigens, Nuclear::Epstein-Barr Virus Nuclear Antigens ENFERMEDADES::virosis::infecciones por virus ADN::infecciones por Herpesviridae::infecciones por virus de Epstein-Barr ENFERMEDADES::enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple::esclerosis múltiple crónica progresiva COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos víricos COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::antígenos::antígenos nucleares::antígenos nucleares del virus de Epstein-Barr |
| description |
Epstein–Barr virus; Human cytomegalovirus; Multiple sclerosis |
| publishDate |
2025 |
| dc.date.none.fl_str_mv |
2025 2025 2025 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11351/12789 |
| url |
http://hdl.handle.net/11351/12789 |
| dc.language.none.fl_str_mv |
Inglés |
| language_invalid_str_mv |
Inglés |
| dc.relation.none.fl_str_mv |
Journal of Neurology;272 https://doi.org/10.1007/s00415-024-12763-w |
| dc.rights.none.fl_str_mv |
Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess |
| rights_invalid_str_mv |
Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.publisher.none.fl_str_mv |
Springer |
| publisher.none.fl_str_mv |
Springer |
| dc.source.none.fl_str_mv |
Scientia reponame:Scientia. Dipòsit d'Informació Digital del Departament de Salut instname:Departament de Salut de la Generalitat de Catalunya (DS) |
| instname_str |
Departament de Salut de la Generalitat de Catalunya (DS) |
| reponame_str |
Scientia. Dipòsit d'Informació Digital del Departament de Salut |
| collection |
Scientia. Dipòsit d'Informació Digital del Departament de Salut |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869409390611660800 |
| spelling |
Increased EBNA1-specific antibody response in primary-progressive multiple sclerosisCarbonell Mirabent, PereComabella Lopez, ManuelHegen, HaraldVillar, Luisa MRejdak, KonradSao Aviles, AugustoBehrens, MalinaSastre Garriga, JaumeMongay-Ochoa, NeusFissolo, Nicolás MiguelGutiérrez Ruiz, LucíaVillacieros-Álvarez, JavierMontalban, XavierImmunoglobulinesEsclerosi múltipleInfeccions per virus d'Epstein-BarrAntígensDISEASES::Virus Diseases::DNA Virus Infections::Herpesviridae Infections::Epstein-Barr Virus InfectionsDISEASES::Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases, CNS::Multiple Sclerosis::Multiple Sclerosis, Chronic ProgressiveCHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, ViralCHEMICALS AND DRUGS::Biological Factors::Antigens::Antigens, Nuclear::Epstein-Barr Virus Nuclear AntigensENFERMEDADES::virosis::infecciones por virus ADN::infecciones por Herpesviridae::infecciones por virus de Epstein-BarrENFERMEDADES::enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple::esclerosis múltiple crónica progresivaCOMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos víricosCOMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::antígenos::antígenos nucleares::antígenos nucleares del virus de Epstein-BarrEpstein–Barr virus; Human cytomegalovirus; Multiple sclerosisVirus de Epstein-Barr; Citomegalovirus humano; Esclerosis múltipleVirus d'Epstein-Barr; Citomegalovirus humà; Esclerosi múltipleBackground and objectives The impact of viral infections on disease susceptibility and progression has predominantly been studied in patients with relapse-onset MS (RMS). Here, we determined immune responses to ubiquitous viruses in patients with primary progressive MS (PPMS). Methods Antibody responses to Epstein–Barr virus (EBV), specifically to the latent EBV nuclear antigen 1 and the lytic viral capsid antigen VCA, human herpesvirus 6 (HHV-6), human cytomegalovirus (HCMV), and measles virus were determined in a cohort of 68 PPMS patients with a mean follow-up of 8 years and compared with 66 healthy controls matched for sex and age. Results Compared with controls, PPMS patients showed increased humoral immune responses to the EBV-encoded nuclear antigen-1 (EBNA1), but not to the lytic EBV capsid antigen (VCA) or to other viral antigens. Seroprevalence rates for HCMV were significantly higher in PPMS. Antiviral immune responses at baseline did not correlate with disability progression over time. Discussion Elevated immune responses toward EBNA1 are selectively increased in people with primary progressive disease, indicating a link between EBNA1-targeting immune responses and the development of both RMS and PPMS. Our data also suggest that chronic HCMV infection is associated with progressive MS.Open Access funding enabled and organized by Projekt DEAL. The authors thank Kerstin Stein (University Hospital of Münster, Department of Neurology with Institute of Translational Neurology) for expert technical assistance. This project has received funding from the European Union’s Horizon Europe Research and Innovation Actions under grant no. 101137235 (BEHIND-MS).SpringerInstitut Català de la Salut[Comabella M, Fissolo N] Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Vall d’Hebron Hospital Universitari, Barcelona, Spain., Barcelona, Spain. Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED)-ISCIII, Madrid, Spain. [Hegen H] Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria. [Villar LM] Departments of Neurology and Immunology, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigacion Sanitaria, Madrid, Spain. [Rejdak K] Department of Neurology, Medical University of Lublin, Lublin, Poland. [Sao Avilés A, Sastre Garriga J, Mongay N, Carbonell Mirabent P, Gutiérrez L, Villacieros Álvarez J, Montalban X] Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Vall d’Hebron Hospital Universitari, Barcelona, Spain., Barcelona, Spain. Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED)-ISCIII, Madrid, Spain. [Behrens M] Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, GermanyVall d'Hebron Barcelona Hospital Campus202520252025info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttp://hdl.handle.net/11351/12789Scientiareponame:Scientia. Dipòsit d'Informació Digital del Departament de Salutinstname:Departament de Salut de la Generalitat de Catalunya (DS)InglésJournal of Neurology;272https://doi.org/10.1007/s00415-024-12763-wAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:scientiasalut.gencat.cat:11351/127892026-06-12T09:38:37Z |
| score |
15.812429 |